1033809-93-6 Usage
Derivative of isoindoline
This compound is derived from the isoindoline structure, which is a type of organic compound.
Class of organic compounds
Indoles This compound belongs to the class of organic compounds known as indoles, which are a group of chemical compounds that include a heterocyclic aromatic ring.
Physical appearance
White to off-white solid This describes the appearance of the compound in its solid state.
Molecular weight
163.17 g/mol This is the mass of one mole of the compound, measured in grams.
Use in organic synthesis and pharmaceutical research
Building block for the production of various drugs and bioactive molecules This compound is used as a building block in the synthesis of other compounds, including drugs and bioactive molecules.
Structure
Contains a hydroxyl group, a methyl group, and a dihydrofuran ring This describes the specific functional groups and structural features of the compound.
Therapeutic potential
Studied for its potential therapeutic applications This compound has been researched for its potential use in the treatment of various diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 1033809-93-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,3,8,0 and 9 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1033809-93:
(9*1)+(8*0)+(7*3)+(6*3)+(5*8)+(4*0)+(3*9)+(2*9)+(1*3)=136
136 % 10 = 6
So 1033809-93-6 is a valid CAS Registry Number.
1033809-93-6Relevant articles and documents
DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES
-
Paragraph 0179; 0182, (2014/10/29)
Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds are disclosed that are represented by general formula (I). Also disclosed, are pharmaceutical compositions including these compounds and methods of using these compounds and compositions for the
FUSED HETEROCYCLIC COMPOUND
-
Page/Page column 89, (2009/10/01)
The present invention provides a fused heterocyclic compound having a tyrosine kinase inhibitory action, which is represented by the formula: wherein R1 is a hydrogen atom, a halogen atom, or an optionally substituted group bonded via a carbon atom, a nitrogen atom or an oxygen atom; R2 is a hydrogen atom, or an optionally substituted group bonded via a carbon atom or a sulfur atom, or R1 and R2, or R2 and R3 are optionally bonded to each other to form an optionally substituted ring structure; R3 is a hydrogen atom or an optionally substituted aliphatic hydrocarbon group, or R3 is optionally bonded to the carbon atom on ring A to form an optionally substituted ring structure; ring A is an optionally substituted benzene ring; and ring B is (i) an optionally substituted fused ring, or (ii) a pyridine ring having optionally substituted carbamoyl (the pyridine ring is optionally further substituted).
